The impact of new drug launches on longevity: Evidence from longitudinal, disease-level data from 52 countries, 1982-2001

被引：90

作者：

Lichtenberg F.R. ^{[1
]}

机构：

[1] Graduate School of Business, Columbia University, National Bureau of Economic Research, New York, NY 10027, 614 Uris Hall

来源：

International Journal of Health Care Finance and Economics | 2005年 / 5卷 / 1期

关键词：

Cost-effectiveness; Innovation; Life expectancy; Longevity; Mortality; Pharmaceuticals;

D O I：

10.1007/s10754-005-6601-7

中图分类号：

学科分类号：

摘要：

We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Under conservative assumptions, our estimates imply that the average annual increase in life expectancy of the entire population resulting from new drug launches is about one week, and that the incremental cost effectiveness ratio (new drug expenditure per person per year divided by the increase in life-years per person per year attributable to new drug launches) is about $6750 - far lower than most estimates of the value of a statistical life-year. © 2005 Springer Science+Business Media, Inc.

引用

页码：47 / 73

页数：26

共 22 条

[1]

MEPS H38Codebook: 1999 Full Year Consolidated Data File Codebook, (2002)

[2]

Arias E., United States Life Tables, 2000, National Vital Statistics Reports, 51, 3, (2002)

[3]

Ernst B., Kyle M.K., Ling D., The Long Shadow of Patent Expiration: Do Rx to OTC Switches Provide an Afterlife?, Scanner Data and Price Indexes, (2003)

[4]

Bresnahan T., Gordon R., The Economics of New Goods, (1997)

[5]

Cutler D., McClellan M., Is Technological Change in Medicine Worth It?, Health Affairs, 20, 5, pp. 11-29, (2001)

[6]

Danzon P., Wang Y.R., Wang L., The Impact of Price Regulation on the Launch Delay of New Drugs - A Study of Twenty-Five Major Markets in the 1990s, (2003)

[7]

Folland S., Goodman A., Stano M., The Economics of Health and Health Care, (2001)

[8]

Getzen T., Health Economics: Fundamentals and Flow of Funds, (1997)

[9]

The 10/90 Report on Health Research 2001-2002, (2002)

[10]

Holcombe G., Et al., Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone, New England Journal of Medicine, 348, 8, pp. 694-701, (2003)

← 1 2 3 →